Lee Christian, Ahsan Hana, Chae Hoon, Esnard Danielle M, Broussard David, Hart Stuart, Allain Alex, Bond Brittany, Busch Eric, Jhita Preya, Matte Melissa, Stedman Robin, Lessing Jacob, Koveleskie Joseph, Nossaman Bobby D
The University of Queensland Medical School, Ochsner Clinical School, New Orleans, LA.
Department of Internal Medicine, Rowan University School of Osteopathic Medicine, Stratford, NJ.
Ochsner J. 2022 Winter;22(4):292-298. doi: 10.31486/toj.22.0064.
Studies have proposed that the routine use of the modified gamma-cyclodextrin, sugammadex, could provide perioperative time savings. However, these investigations have been limited to small group analyses. The purpose of this study was to test the effectiveness of sugammadex on perioperative times when compared to neostigmine under general clinical practice conditions following rocuronium-induced neuromuscular blockade for laparoscopic cholecystectomy. Following institutional review board approval, data from 1,611 consecutive surgical records for laparoscopic cholecystectomy were reviewed. Patient characteristics, type of primary neuromuscular blocking reversal agent, operating room (OR) discharge times, and postanesthesia care unit (PACU) recovery times were the measures of interest. Equivalence testing was used to determine the between-group differences of the reversal agents in the two perioperative time periods of interest. OR discharge times averaged 10.9 (95% CI, 10-11.8) minutes for patients administered sugammadex and 8.9 (95% CI, 8.2-9.7) minutes for patients administered neostigmine. PACU recovery times averaged 77.6 (95% CI, 74.1-81.1) minutes for sugammadex and 68.6 (95% CI, 65.9-71.3) minutes for neostigmine. Equivalence testing demonstrated no improvement in the two perioperative times with sugammadex. These results suggest no perioperative time savings with sugammadex when compared to neostigmine following laparoscopic cholecystectomy under general clinical practice conditions.
研究表明,常规使用改良γ-环糊精舒更葡糖钠可节省围手术期时间。然而,这些研究仅限于小样本分析。本研究的目的是在罗库溴铵诱导的神经肌肉阻滞用于腹腔镜胆囊切除术后的一般临床实践条件下,测试舒更葡糖钠与新斯的明相比对围手术期时间的有效性。经机构审查委员会批准后,回顾了1611例连续腹腔镜胆囊切除术的手术记录数据。患者特征、主要神经肌肉阻滞剂逆转剂类型、手术室(OR)出院时间和麻醉后护理单元(PACU)恢复时间是感兴趣的指标。采用等效性检验来确定两种逆转剂在两个感兴趣的围手术期时间段内的组间差异。接受舒更葡糖钠治疗的患者的手术室出院时间平均为10.9(95%CI,10-11.8)分钟,接受新斯的明治疗的患者为8.9(95%CI,8.2-9.7)分钟。舒更葡糖钠组的PACU恢复时间平均为77.6(95%CI,74.1-81.1)分钟,新斯的明组为68.6(95%CI,65.9-71.3)分钟。等效性检验表明,舒更葡糖钠在两个围手术期时间上没有改善。这些结果表明,在一般临床实践条件下,腹腔镜胆囊切除术后,与新斯的明相比,舒更葡糖钠并不能节省围手术期时间。